Credit: Pixabay / CC0 Public Domain

The scientific sessions of the Society of Cardiovascular Angiography and Interventions (SCAI) in 2022 presented new data from a study of more than 100 million hospitalizations using machine learning. The results show that percutaneous coronary intervention (PCI) is safe and is increasing among cancer patients.

Cardioancology is a field of cardiology that focuses on the detection, monitoring and treatment of cardiovascular disease among cancer patients. Cancer patients tend to be underrepresented in cardiovascular clinical trials, leading to a lack of data on safe and effective treatment options for this cohort of patients.

To better understand treatment regimens, the researchers conducted the country’s first multi-year representative multi-year cardio-cancer study of mortality from thrombocytopenia, a condition that causes low blood platelet counts, and coronary intervention, including PCI, using increased machine learning (PS) and machine learning. Using the National Stationary Sampling (NIS) for 2016-2018, the researchers analyzed 101,521,656 hospitalized adult patients6,456,777 (6.36%) had active cancer, of which 6.14% had thrombocytopenia.

Among patients with thrombocytopenia, patients with active cancer had significantly less catheterization of the left heart (1.88 vs. 5.41%) and PCI (0.48 vs. 1.35%) compared with patients without active cancer. Among cancer patientsin patients with thrombocytopenia most often acute myocardial infarction (4.06 vs. 2.35%) and obtain intravascular ultrasound (62.65 vs. 56.75%). PCI almost doubled from 2016 to 2018 among patients with thrombocytopenia (10.33 vs. 6.16%). In multivariate regression in PCI, neither active cancer (OR 0.89, 95% CI 0.45–1.75; p = 0.738) nor any of the 32 primary malignancies studied significantly increased mortality.

“Our study focused on using big data power and artificial intelligence to provide reliable, reliable and relevant results to manage appropriately tailored interventions for cardio-cancer patients“- said Dominic J. Manlesun, MD, Ph.D., Ph.D., MPH, is an associate professor at Anderson Anderson University in Texas at the Cancer Center in Houston, Texas, and a senior research scientist. “We hope to reduce inadequate treatment among this patient population by providing clinicians with compelling evidence of the safety and efficacy of revascularization techniques for this particular group of patients.”

Moving forward, researchers hope that the use of AI technology will allow researchers and physicians to increase the amount of sophisticated real-time data collection, ultimately advancing patient care techniques faster than traditional methods.

A closer look at the impact of COVID-19 on cardiac oncology

Additional information:

Citation: A nationwide hospitalization study shows that percutaneous coronary intervention is safe for cardiac cancer patients (2022, May 19), received May 19, 2022 from -hospitalizations-percutaneous-intervention- .html

This document is subject to copyright. Except for any honest transaction for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.

Previous articleRihanna and A $ AP Rocky are reportedly welcoming the boy!
Next articleNumber of MTA passengers continues to rebound pandemic, agency launches DineAWAY campaign to help restaurants